Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mifobate (SR-202) is a potent and specific antagonist of PPARγ. Mifobate shows antiobesity, antidiabetic and antiatherosclerotic effects[1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 97.00 | |
5 mg | In stock | $ 288.00 | |
10 mg | In stock | $ 428.00 | |
25 mg | In stock | $ 686.00 | |
50 mg | In stock | $ 969.00 | |
100 mg | In stock | $ 1,280.00 |
Description | Mifobate (SR-202) is a potent and specific antagonist of PPARγ. Mifobate shows antiobesity, antidiabetic and antiatherosclerotic effects[1]. |
Targets&IC50 | PPARγ:140 μM (IC50) |
In vitro | SR-202 is a new synthetic PPARgamma antagonist,, which inhibits both TZD-stimulated recruitment of the coactivator steroid receptor coactivator-1 and TZD-induced transcriptional activity of the receptor.?In cell culture, SR-202 efficiently antagonizes hormone- and TZD-induced adipocyte differentiation[1]. |
In vivo | In vivo, decreasing PPARgamma activity, either by treatment with SR-202 or by invalidation of one allele of the PPARgamma gene, leads to a reduction of both high fat diet-induced adipocyte hypertrophy and insulin resistance.?These effects are accompanied by a smaller size of the adipocytes and a reduction of TNFalpha and leptin secretion.?Treatment with SR-202 also dramatically improves insulin sensitivity in the diabetic ob/ob mice[1]. |
Synonyms | SR-202 |
Molecular Weight | 358.65 |
Formula | C11H17ClO7P2 |
CAS No. | 76541-72-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 35.87 mg/mL (100.01 mM), Sonication and heating are recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mifobate 76541-72-5 DNA Damage/DNA Repair Metabolism PPAR diabetes Peroxisome proliferator-activated receptors adipocyte stimulation antiobesity transcriptional SR 202 type 2 obesity differentiation SR-202 SR202 activity selective antidiabetic inhibit Inhibitor inhibitor